Core Insights - Serina Therapeutics congratulates its strategic partner Juvenescence Ltd. for securing $150 million in Series B financing led by M42, which will enhance their drug development capabilities [1][2][3] - The partnership aims to establish a drug development hub in Abu Dhabi, integrating AI-enabled drug discovery with advanced clinical infrastructure to expedite the creation of innovative therapies targeting age-related diseases [2][3] - Juvenescence's leadership has a proven track record in biopharma, having previously led significant deals and developed medicines with peak annual sales totaling $30 billion [7][8] Company Overview - Serina Therapeutics is a clinical-stage biotechnology company focused on developing drug candidates for neurological diseases and other indications, utilizing its proprietary POZ Platform to enhance the efficacy and safety of various therapeutic modalities [4] - Juvenescence is an AI-enabled biotech company dedicated to extending healthy lifespan by targeting core aging mechanisms to treat age-related diseases [6][8] - M42, a global health company, combines AI, technology, and genomics to innovate healthcare solutions, operating over 480 facilities across 26 countries [9][11]
Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42